Cargando…
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease of the central nervous system, with an estimated 5 000 000 cases worldwide. Historically characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, PD pathology is now known...
Autores principales: | Werner, Milton H., Olanow, C. Warren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770606/ https://www.ncbi.nlm.nih.gov/pubmed/34816484 http://dx.doi.org/10.1002/mds.28858 |
Ejemplares similares
-
A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic
por: Kieburtz, Karl, et al.
Publicado: (2020) -
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study
por: Poewe, Werner, et al.
Publicado: (2021) -
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
por: Mahlknecht, Philipp, et al.
Publicado: (2022) -
Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
por: Campese, Nicole, et al.
Publicado: (2021) -
Plant casein kinases phosphorylate and destabilize a cyclin-dependent kinase inhibitor to promote cell division
por: Qu, Li, et al.
Publicado: (2021)